8-K: Beta Bionics Unveils Strong Real-World iLet Data at ADA Event, Demonstrating Significant Glycemic Improvements

Beta Bionics, Inc. announced compelling real-world data for its iLet Bionic Pancreas, showing significant improvements in glycemic control and hypoglycemia management across diverse user groups, including those transitioning from other insulin therapies.

Summary

• Beta Bionics, Inc. hosted its first Investor and Analyst Event on June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA).
• The company released updated real-world data for its iLet Bionic Pancreas, collected from 16,439 users who uploaded continuous glucose monitor (CGM) readings between May 19, 2023, and May 18, 2025.
• For 14,952 iLet users with baseline HbA1c data, there was an overall improvement from an average baseline HbA1c of 8.9% to an average Glucose Management Indicator (GMI) of 7.3% on the iLet.
• Over 84% of these users met the ADA's hypoglycemia goals of less than 4% time below 70 mg/dL and less than 1% time below 54 mg/dL.
• Users previously on multiple daily injections (MDI) (8,802 users) showed an improvement from an average baseline HbA1c of 9.2% to an average GMI of 7.3% on the iLet, with over 85% meeting ADA hypoglycemia goals.
• Users transitioning from competitive hybrid-closed loop (HCL) systems (2,910 users) improved from an average baseline HbA1c of 8.1% to an average GMI of 7.3% on the iLet, with over 83% meeting ADA hypoglycemia goals.
• Similar improvements were observed regardless of provider practice type, with users treated in endocrinology (13,566 users) and primary care (1,036 users) practices showing an average improvement from 8.9% baseline HbA1c to 7.3% GMI.
• Approximately 16% of iLet users (2,416 users) operated the pump in a fully-closed loop manner (announcing less than one meal per day), achieving an improvement from an average baseline HbA1c of 9.4% to an average GMI of 7.5%, with approximately 83% meeting ADA hypoglycemia goals and an average time in range of approximately 62%.
• 530 iLet users who announced no meals over a 21-day period improved from an average baseline HbA1c of 9.4% to an average GMI of 7.4%, with approximately 86% meeting ADA hypoglycemia goals.
• The iLet's adaptive algorithm reached a near steady-state GMI of 7.4% (from an 8.9% baseline HbA1c) in approximately two days after initiation, demonstrating a rapid warm-up period.
• The company also provided a demonstration of its patch pump in development, which features a reusable controller and disposable cartridge, targeting commercialization by the end of 2027.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive real-world data for the iLet, demonstrating significant improvements in glycemic control and hypoglycemia management across diverse user groups, including those transitioning from competitive systems. The announcement of a new patch pump in development further adds to the positive outlook and future growth potential.

Positives

• The iLet Bionic Pancreas demonstrated significant overall improvement in glycemic control, reducing average baseline HbA1c from 8.9% to an average GMI of 7.3%.
• A high percentage of users (over 84%) met the American Diabetes Association's (ADA) stringent hypoglycemia goals.
• The iLet proved effective for users transitioning from multiple daily injections (MDI), showing a substantial reduction from 9.2% baseline HbA1c to 7.3% GMI.
• The system also showed strong performance for users switching from competitive hybrid-closed loop (HCL) systems, improving their average baseline HbA1c of 8.1% to 7.3% GMI.
• The iLet's benefits were consistent across different provider practice types, including primary care, indicating broader accessibility and ease of use for various healthcare settings.
• The adaptive algorithm of the iLet demonstrated a rapid warm-up time, reaching near steady-state GMI in approximately two days after initiation.
• A significant portion of users (approximately 16%) successfully utilized the iLet in a fully-closed loop manner with minimal meal announcements, achieving excellent glycemic outcomes and time in range.
• The development of a new patch pump with a reusable controller and disposable cartridge, targeting commercialization by the end of 2027, indicates future product innovation and market expansion potential.

Risks

• Risks inherent in developing product candidates.
• Future results from the Company's ongoing and future studies and clinical trials may not be consistent with interim, initial, or preliminary results or results from prior preclinical studies or clinical trials.
• The Company's ability to obtain adequate financing to fund its product development and other expenses.
• Real-world data or future results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials.
• Trends in the industry.
• The Company's relationships with its existing and future collaboration partners.
• The legal and regulatory framework for the industry.
• Future expenditures.
• Potential impacts of global macroeconomic conditions.

Future Outlook

The Company anticipates continued benefits from the iLet, including sustained overall improvements in glycemic control. It plans ongoing and future studies and clinical trials to further assess product candidates. A significant future milestone is the commercialization of the new mint patch pump, which is targeted for the end of 2027, aiming to expand the addressable market and streamline access through pharmacy channels. The company also expects to continue its regulatory development plans and execute its multi-channel reimbursement strategy.

Management Comments

• Management believes in the potential benefits of the iLet, including the overall improvement reflected in the real-world data between average baseline HbA1c and average GMI on the iLet.
• The adaptive algorithm of the iLet is designed to learn and adjust automatically, simplifying diabetes management for both users and healthcare providers.
• The development of the patch pump aims to provide a seamless user experience with features like a reusable controller, disposable cartridge, and compatibility with leading CGM systems, while also offering potential business advantages such as cost-effective manufacturing and reduced environmental waste.

Industry Context

Beta Bionics operates in the highly competitive automated insulin delivery (AID) market. The iLet Bionic Pancreas differentiates itself with an adaptive algorithm that simplifies use by eliminating the need for carb counting and manual settings adjustments, a significant departure from traditional hybrid-closed loop (HCL) systems offered by competitors like Tandem (t:slim X2, Mobi), Insulet (Omnipod 5), and Medtronic (MiniMed series). The real-world data presented suggests the iLet's ability to achieve superior glycemic outcomes even for patients transitioning from these established competitive systems. The planned introduction of a patch pump by 2027 indicates a strategic move to capture a broader market segment, potentially leveraging pharmacy channels for easier access and 'pay-as-you-go' economics, aligning with evolving industry trends towards more user-friendly and accessible diabetes management solutions.

Comparison to Industry Standards

• The iLet's performance was benchmarked against the HbA1c of adults with Type 1 Diabetes (T1D) in the United States, as reported in the Pettus et al. study (Diabetes Care 2019;42:2220-2227), which included data from 31,430 adults. iLet users demonstrated a significant shift towards lower GMI values compared to the historical HbA1c distribution in the Pettus study.
• The iLet consistently enabled a high percentage of users (over 84% overall, >85% for MDI users, >83% for competitive HCL users) to meet the American Diabetes Association's (ADA) hypoglycemia goals of less than 4% time below 70 mg/dL and less than 1% time below 54 mg/dL, indicating strong safety and efficacy.
• For users transitioning from competitive HCL systems, including Tandem's t:slim X2 and Mobi, Insulet's Omnipod 5, and Medtronic's MiniMed 670G, 720G, 750G, 760G, 770G, and 780G, the iLet still showed an average improvement from 8.1% baseline HbA1c to 7.3% GMI, suggesting a superior or at least comparable outcome with potentially less user burden.

Stakeholder Impact

• **Shareholders/Investors**: The strong positive real-world data for the iLet, coupled with future product development plans, is likely to increase investor confidence and potentially lead to a positive impact on share price.
• **Patients (Users)**: Patients using the iLet are experiencing significant improvements in glycemic control (lower HbA1c/GMI) and better hypoglycemia management, leading to improved health outcomes and quality of life. The simplified use of the device (no carb counting, adaptive algorithm) reduces patient burden.
• **Healthcare Providers (HCPs)**: The iLet's effectiveness across different provider types (endocrinology and primary care) and its simplified management (no manual settings adjustments) empower a broader range of HCPs to effectively treat diabetes patients, potentially expanding access to advanced care.
• **Competitors**: The data indicates that the iLet is effective even for users switching from competitive HCL systems, suggesting a strong competitive position and potentially challenging the market share of existing players.
• **Suppliers/Partners**: Continued success and expansion of the iLet and future products like the patch pump could lead to increased demand for components and services from suppliers and collaboration partners.

Next Steps

• Continue commercialization efforts for the iLet Bionic Pancreas.
• Conduct ongoing and future studies and clinical trials to further evaluate product candidates.
• Advance regulatory development plans for the iLet and other product candidates.
• Pursue the commercialization of the mint patch pump, targeting launch by the end of 2027.
• Implement and expand the multi-channel reimbursement strategy, including pharmacy channel access.

Key Dates

Recommendation

Keywords

Diabetes, iLet Bionic Pancreas, Automated Insulin Delivery, Continuous Glucose Monitor, HbA1c, Glucose Management Indicator, Type 1 Diabetes, Insulin Pump, Closed-Loop System, Beta Bionics, American Diabetes Association, Medical Device, Endocrinology, Primary Care, Multiple Daily Injections, Hybrid-Closed Loop, Patch Pump